SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                  FORM 12b-25


                                       Commission File Number 0-19627
                                                              -------

                          NOTIFICATION OF LATE FILING
                                                          
(Check One): [_] Form 10-K  [_] Form 11-K  [_] Form 20-F  [X] Form 10-Q  [_] Form N-SAR



For Period Ended:  March 31, 2000
                   --------------
[_]  Transition Report on Form 10-K      [_]  Transition Report on Form 10-Q
[_]  Transition Report on Form 20-K      [_]  Transition Report on Form N-SAR
[_]  Transition Report on Form 11-K

For the Transition Period Ended:  N/A
                                 -----------------------------------------------

    Read attached instructions sheet before preparing form.  Please print or
type.

    Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

    If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:  N/A
                                                         ---


                        Part I.  Registrant Information

Full name of registrant   BioLase Technology, Inc.
                          ------------------------------------------------------
Former name if applicable

- -------------------------------------------------------------------------------
Address of principal executive office (street and number)
                           981 Calle Amanecer
- --------------------------------------------------------------------------------

City, State and Zip Code   San Clemente, CA  92673
                           -----------------------------------------------------

                       Part II.  Rule 12b-25 (b) and (c)

    If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the
following should be completed.  (Check appropriate box.)

[X] (a) The reason described in reasonable detail in Part III of this form could
    not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form
    10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
    before the 15th calendar day following the prescribed due date; or the
    subject quarterly report or transition report on Form 10-Q or portion
    thereof will be filed on or before the fifth calendar day following the
    prescribed due date; and

[_] (c) The accountant's statement or other exhibit required by Rule 12b-25 (c)
    has been attached if applicable.


                              Part III. Narrative

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-
Q, N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed.).

    The Company was unable to file its Quarterly Report on Form 10-Q in a timely
manner due to the temporary unavailability of resources required to compile such
quarterly report.  The Company has overcome this issue which should provide for
improved and timely reporting ability in the future.

    The Company anticipates the filing of its Quarterly Report on Form 10-Q to
occur no later than 5 calendar days following the prescribed due date in
accordance with Rule 12b-25, section (b)(2)(ii) of the Regulations under the
Securities Exchange Act of 1934, should such an extension be granted by the
Securities and Exchange Commission.

                           Part IV. Other Information

    (1)  Name and telephone number of person to contact in regard to this
notification

    Stephen R. Tartamella      949          361-1200, extension 111
    ----------------------------------------------------------------------------
          (Name)            (Area Code)         (Telephone Number)

    (2)  Have all other periodic report required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such a report(s) been filed?  If the answer is
no, identify report(s).
                                                           [X] Yes  [_]  No

    (3)  Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                           [X] Yes  [_]  No

    If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

    The Company's results of operations reflected sales of approximately
$1,527,000 for the three months ended March 31, 2000 compared to the $1,786,000
reported for the comparable period in 1999.  The net loss for the three months
ended March 31, 2000 was approximately $1,032,000, or $0.06 per basic/diluted
share, versus a net loss of $670,000, or $0.04 per basic/diluted share, for the
comparable period in 1999.

                            BioLase Technology, Inc.
- --------------------------------------------------------------------------------
                  (Name of registrant as specified in charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date   May 16, 2000             By  /s/ Stephen R. Tartamella
     -------------------            ----------------------------------
                                    Stephen R. Tartamella, Secretary


    Instruction.  The form may be signed by an executive officer of the
registrant or by any other duly authorized representative.  The name and title
of the person signing the form shall be typed or printed beneath the signature.
If the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.

                             GENERAL INSTRUCTIONS

    1.  This form is required by Rule 12b-25 of the General Rules and
Regulations under the Securities Exchange Act of 1934.

    2.  One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities and Exchange
Commission, Washington D.C. 20549, in accordance with Rule 0-3 of the General
Rules and Regulations under the Act.  The information contained in or filed with
the form will be made a mater of the public record in the Commission files.

    3.  A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of the
registrant is registered.

    4.  Amendments to the notifications must also be filed on Form 12b-25 but
need not restate information that has been correctly furnished.  The form shall
be clearly identified as an amended notification.